

Substitute for Form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	10/582,301
		Filing Date	September 18, 2006
		First Named Inventor	Shuo SHEN
		Art Unit	
		Examiner Name	
Sheet 1 of 1	Attorney Docket Number	5463-2PUS	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T‡
		O. Krokhn et al., "Mass Spectrometric Characterization of Proteins from the SARS Virus", <i>Molecular &amp; Cellular Proteomics</i> 2: 346-356, pp. 1-19, 2003	
		SARS CoV Sequence AY 278741, at <a href="http://athena.bioc.uvic.ca/sars/data/AY278741.gb">http://athena.bioc.uvic.ca/sars/data/AY278741.gb</a>	
		Written Opinion of Application SG 200603918-4, Australian Patent Office	
		X. Wang et al., "Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody", 2005 International Medical Press, 1359-6535, 681-690	
		J. ter Meulen et al., "Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets", <i>THE LANCET</i> , Vol. 363, pp. 2139-2141, June 26, 2004	
		R.H. See et al., "Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus", <i>Journal of General Virology</i> , Vol. 87, pp. 641-650, 2006	
		J. Sui et al., "Evaluation of Human Monoclonal Antibody 80R for Immunoprophylaxis of Severe Respiratory Syndrome by an Animal Study, Epitope Mapping, and Analysis of Spike Variants", <i>Journal of Virology</i> , Vol. 79, No. 10, pp. 5900-5906, May 2005	
		E. Traggiai et al., "An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus", <i>Nature Medicine</i> , Vol. 10, No. 8, pp. 871-875, August 2004	
		T.C. Greenough et al., "Development and Characterization of a Severe Acute Respiratory Syndrome-Associate Coronavirus-Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice: SARS-Neutralizing Monoclonal Antibodies", <i>Journal of Infectious Diseases</i> , Vol. 191, pp. 507-514, February 15, 2005	
		A. Roberts et al., "Therapy with a Severe Acute Respiratory Syndrome-Associated Coronavirus-Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters: Mab Therapy Reduces SARS-CoV Disease Severity", <i>Journal of Infectious Diseases</i> , Vol. 193, pp. 685-692, March 1, 2006	
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MM/			

Examiner Signature	/Mary Mosher/	Date Considered	07/01/2008
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.